249 related articles for article (PubMed ID: 29604233)
1. Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
Cramer SP; Simonsen HJ; Varatharaj A; Galea I; Frederiksen JL; Larsson HBW
Ann Neurol; 2018 May; 83(5):902-914. PubMed ID: 29604233
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.
Knudsen MH; Lindberg U; Frederiksen JL; Vestergaard MB; Simonsen HJ; Varatharaj A; Galea I; Blinkenberg M; Sellebjerg F; Larsson HBW; Cramer SP
Mult Scler Relat Disord; 2022 Jul; 63():103891. PubMed ID: 35661562
[TBL] [Abstract][Full Text] [Related]
3. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
Preziosa P; Storelli L; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
[TBL] [Abstract][Full Text] [Related]
4. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
7. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier permeability measured using dynamic contrast-enhanced magnetic resonance imaging: a validation study.
Varatharaj A; Liljeroth M; Darekar A; Larsson HBW; Galea I; Cramer SP
J Physiol; 2019 Feb; 597(3):699-709. PubMed ID: 30417928
[TBL] [Abstract][Full Text] [Related]
9. Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
Guerra T; Caputo F; Orlando B; Paolicelli D; Trojano M; Iaffaldano P
Neurol Sci; 2021 Nov; 42(11):4647-4655. PubMed ID: 33677753
[TBL] [Abstract][Full Text] [Related]
10. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
11. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
12. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F
Ann Neurol; 2016 Jun; 79(6):950-8. PubMed ID: 27038238
[TBL] [Abstract][Full Text] [Related]
13. Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.
Grahl S; Bussas M; Wiestler B; Eichinger P; Gaser C; Kirschke J; Zimmer C; Berthele A; Hemmer B; Mühlau M
Neurotherapeutics; 2021 Oct; 18(4):2589-2597. PubMed ID: 34561843
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
[TBL] [Abstract][Full Text] [Related]
15. Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Klotz L; Grützke B; Eveslage M; Deppe M; Gross CC; Kirstein L; Posevitz-Fejfar A; Schneider-Hohendorf T; Schwab N; Meuth SG; Wiendl H
BMC Neurol; 2015 Jun; 15():96. PubMed ID: 26099927
[TBL] [Abstract][Full Text] [Related]
16. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
[TBL] [Abstract][Full Text] [Related]
19. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.
Soon D; Altmann DR; Fernando KT; Giovannoni G; Barkhof F; Polman CH; O'Connor P; Gray B; Panzara M; Miller DH
J Neurol; 2007 Mar; 254(3):306-14. PubMed ID: 17277910
[TBL] [Abstract][Full Text] [Related]
20. Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
Fiander MDJ; Bhan V; Stewart SA; Parks NE
Can J Neurol Sci; 2019 Jul; 46(4):455-458. PubMed ID: 31113500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
